Eli Lilly's (LLY) Prasugrel Significantly Reduced Heart Attacks Compared to Clopidogrel
More News related to LLY
- Lilly Completes Cash Tender Offer for ImClone Systems
- Lilly and International Council of Nurses Win Partnership Award From the U.S. Chamber of Commerce Business Civic Leadership Center
- Lilly Selects ICON to Manage its Clinical Data Management Business Outside the US
- ImClone Systems Announces Clearance of Tender Offer by German Federal Cartel Office
- Eli Lilly (LLY) In License and Supply Agreement With United Therapeutics (UTHR)
More News related to Corporate News
- Citi Initiates Coverage on US Soft Drink Makers
- William Blair Initiates Coverage on Data Networking Stocks
- Caris Starts Coverage on Ariba (ARBA), Concur (CNQR), salesforce.com (CRM), Taleo (TLEO)
- Oppenheimer Initiates Coverage on ViroPharma (VPHM)
- Oppenheimer Initiates Coverage on Cadence Pharmaceuticals (CADX) with an Outperform
A sub-analysis of the TRITON-TIMI 38 clinical trial showed that treatment with Eli Lilly's (NYSE: LLY) prasugrel compared with clopidogrel significantly reduced the risk of new or recurrent heart attacks (7.4% vs. 9.7%, p<0.0001), regardless of whether the events occurred around the time of an artery-opening procedure known as percutaneous coronary intervention, or if they occurred spontaneously during the longer-term maintenance phase. The analysis was presented today at the European Society of Cardiology in Munich, Germany.
The main TRITON-TIMI 38 clinical trial, for which overall results were previously published in the New England Journal of Medicine in November 2007, compared prasugrel with clopidogrel (Plavix(R)/Iscover(R)) in patients with ACS undergoing PCI. In the primary analysis of the trial, prasugrel reduced the risk of the composite of cardiovascular death, heart attack or stroke by 19 percent, with an increased risk of major bleeding compared with clopidogrel (2.4% vs. 1.8%).
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide.
Related Categories
Corporate NewsStocks Mentioned
+0.52Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
